Physician profile
Angelito Tecson
NPI 1144283219
$2,321.35
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $272 · 2021: $723 · 2022: $44.04 · 2023: $49.56 · 2024: $21.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $707.71 | 2019-2021 | |
| Novo Nordisk INC | $243.58 | 2019-2021 | |
| Daiichi Sankyo INC. | $235.19 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $142.43 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $124.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.37 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $109.19 | 2020 | |
| Dexcom, INC. | $101.55 | 2021 | |
| Glaxosmithkline, LLC. | $94.43 | 2020-2022 | |
| Horizon Therapeutics Plc | $84.68 | 2019 | |
| Boston Scientific Corporation | $84.34 | 2019 | |
| Allergan, INC. | $80.10 | 2019-2020 | |
| Pfizer INC. | $46.49 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $32.28 | 2023 | Quviviq |
| Lilly USA, LLC | $29.04 | 2021-2023 | Mounjaro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.26 | 2021 | |
| Abbott Laboratories | $21.17 | 2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $17.08 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.28 | 2022 | |
| Abbvie INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelito Tecson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.